*National Institute for Health and Care Excellence logo *

***Public Involvement Programme***

A guide for preparing to be a patient expert

## Who is this for?

This is aimed at people who are attending the Technology Appraisal Committee or a Highly Specialised Technology meeting as a Patient Expert. In this document, we will refer to you as ‘you’ and sometimes as ‘Patient Expert’ and sometimes we will refer to the ‘appraisal’ as ‘evaluation’.

It contains general information on what to expect as a Patient Expert, how you can prepare for the meeting, what you might expect in the meeting and what will happen afterwards.

Before the meeting, the project manager for the Committee will send you additional information including the committee papers, specifically about the appraisal in which you are to take part.

If you have any questions or concerns or need help including practicalities, such as needing to be accompanied by your carer, please contact the Public Involvement Programme at [pip@nice.org.uk](mailto:pip@nice.org.uk) or by calling 0161 870 3020.

Although there are 3 processes for technology appraisals at NICE, Single Technology Appraisal (STA), Highly Specialised Technologies (HST) and Multiple Technology Appraisal (MTA) the patient expert involvement is the same in all.

## Contents

1. [**Before the meeting**](#Before)[**page 3**](#Before)

[1a](#Statement) [Short personal statement](#Statement) [page 3](#Statement)

[1b](#Preparation) [Preparation](#Preparation) [page 3](#Preparation)

[1c](#Identifying) [Identifying key points](#Key_points) [page 4](#Key_points)

[1d](#Questions) [Questions you may be asked](#Questions) [page 4](#Questions)

1. [**At the meeting**](#At)[**page 5**](#At)

[2a](#Venue) [Venue](#Venue) [page 5](#Venue)

[2b](#Attendance) [Attendance](#Attendance) [page 5](#Attendance)

[2c](#Meetting_style) [Meeting style](#Meetting_style) [page 5](#Meetting_style)

[2d](#Introductions) [Introductions](#Introductions) [page 6](#Introductions)

[2e](#Conflict) [Conflict of interest](#Conflict) [page 6](#Conflict)

[2f](#Presentation) [The presentation](#Presentation) [page 6](#Presentation)

[2g](#discussion) [Committee discussion](#discussion) [page 7](#discussion)

[2h](#Equalities) [Equalities](#Equalities) [page 7](#Equalities)

[2i](#Closing) [Closing comment](#Closing) [page 8](#Closing)

1. [**After you leave the meeting**](#After)[**page 9**](#After)

[3a](#Committee_decision) [The Committee’s decision](#Committee_decision) [page 9](#Committee_decision)

[3b](#After_the_Committee_deci) [After the Committee’s decision](#After_the_Committee_deci) [page 11](#After_the_Committee_deci)

1. [**Claiming expenses**](#Expenses)[**page 12**](#Expenses)
2. [**What to do if you are contacted by the press**](#Press)[**page 13**](#Press)
3. [**Observing Committee meetings from the public gallery**](#Observing)[**page 13**](#Observing)
4. [**Checklist**](#Checklist)[**page 14**](#Checklist)

**1** Before the Meeting

## 1a Short personal statement & technical engagement

Before the Committee meeting, all experts are asked to submit a personal statement to the Technology Appraisal Committee. This is done to give the Committee information about the Patient Expert’s experience of the condition and evaluation of the treatment. The statement helps Committee members understand the views and experience of each Patient Expert and enables them to focus their questions.

The personal statement will also help the committee ‘lay lead’ pull together key patient issues to present in the meeting. The ‘lay lead’ is 1 of 2 Committee lay members who has special responsibility for highlighting patient issues. The earlier you can send us your personal statement, the better, as it helps the ‘lay lead’ incorporate the main patient issues into the slides.

Personal statements are produced using a template which has or will be sent to you as part of your invitation to act as Patient Expert. Personal statements are circulated to the Committee in advance of the meeting and are published on the [NICE website](http://www.nice.org.uk), alongside all other relevant documentation seen by the Committee for that topic, after the meeting. If you do not wish your personal statement to be made available on the NICE website please discuss with us. We will see if it’s possible for a redacted version to be included in the papers that are uploaded to our website.

You may produce your own personal statement or, if your nominating organisation has already made a statement, you can state that you wish to agree with that, by indicating so on the appropriate form (which is also provided as part of your invitation).

**Technical engagement**: All stakeholders (including patient organisations) are invited to take part in the technical engagement consultation and will be sent the technical engagement documentation. As well as your personal statement you may be invited to take part in a teleconference or Zoom call with the NICE technical team and clinical experts for this topic to discuss key areas of uncertainty and seek your feedback and comment.

## 1b Preparation

In preparation for the meeting, you should consider whether you would like to request a closed session so that any personal or sensitive information that you do not wish to disclose in public may be considered in private (see section 2b). If so, it will be necessary to discuss this with the Chair before the meeting. Please contact your nominated public involvement adviser as soon as possible before the meeting if you think this would be helpful.

You can also prepare for the meeting by:

1. Attending the patient expert briefing session:

* Your named public involvement adviser will invite you to attend a patient expert briefing session (via Zoom) in the month prior to your committee meeting. Sessions are held monthly, if you would like to attend earlier than the month before, please contact your adviser.
* During the briefing session outlines how the meeting will run and what you can expect and tips for navigating the committee papers you will receive ahead of the meeting.

1. Thinking about the condition and/or therapy:

* What is your background and experience of the condition and therapy under evaluation?
  + When did you first come into contact with the condition and/or therapy?
  + What impact have the condition and therapy had on your life?
  + If you are a patient or carer yourself, think about significant events, such as when treatment started and completed, onset of adverse or beneficial effects, and changes in quality of life. In the meeting, you should be factual and precise – for example, if you experienced pain, think about how severe it was and how long it lasted.
* In your view, what are the benefits and downsides of the therapy under evaluation?
* How does the therapy compare with other therapies?
* What difference (if any) has the therapy under evaluation made to you?
* What would be the implication if the therapy was not available?
* What is the impact on your home life, social life and your ability to work?
* What is the impact on your family and friends?

1. Familiarising yourself with the appraisal/evaluation process. The [NICE website](http://www.nice.org.uk/about/what-we-do/our-programmes/nice-guidance/nice-technology-appraisal-guidance) contains useful information. The Public Involvement Programme has also prepared [information sheets](http://www.nice.org.uk/about/nice-communities/public-involvement/develop-NICE-guidance) on other stages of the appraisal/evaluation process. You need to have a basic understanding of:

* why technologies are evaluated
* how decisions are made
* the implication of NICE guidance for the NHS

It is sometimes useful to be familiar with the previous input into the evaluation from patient and carer organisations and other consultees found in the committee papers (stakeholders who can submit statements and lodge appeals), but as a Patient Expert your role is solely to represent your own views and experience.

You will receive a lot of information from NICE before the meeting **but are not expected to read through all of it in detail.**

You will have access to the committee papers through our online system once you have signed NICE’s confidentiality form. **You must not share them with anybody else** as they have not signed a confidentiality form. The papers are a compilation of the documents provided by the stakeholders such as the company, patient organisations and others and include the independent academic review group’s report on the company’s submission.

You should receive the committee papers 1 – 2 weeks ahead of the meeting, however there can sometimes be a delay with the release of the papers due to necessary updates or amendments. Please get in touch with your PIP adviser if you haven’t received them the week of the committee meeting. To ensure that you receive the documentation as early as possible, it is important that you complete and return your confidentiality form. If this form has not been completed and returned, you will not be able to receive any documentation.

Experts attending the Committee meeting are not asked to make a presentation, but are offered the opportunity to introduce themselves, respond to specific questions from Committee members and make a closing comment if they find there is anything of relevance to the Committee’s discussion that they have not yet contributed.

## 1c Identifying key points

What are the main issues for this technology from the patient’s or carer’s perspective? You may find it helpful to identify 3 or 4 key points that you think are most important when considering the patient or carer view of the therapy being appraised. These are the points you need to try to include in the Committee discussion or in your closing statement.

## 1d Questions you may be asked

Although it is not possible to know exactly what you will be asked in advance of the meeting, questions will typically be about your personal experience of the condition and therapy. Occasionally, there may be very few questions for you if the evidence and submissions are so clear that no extra clarification is needed. It is not possible to know how many or few questions there might be in advance.

# 2 At the meeting

## 2a Venue

**Due to the coronavirus pandemic, we will be holding our advisory committee meetings virtually via Zoom until further notice.**

Technology Appraisal Committee meetings are currently held in either Central London or Central Manchester, often at the NICE offices. The Committee itself is quite large and, as meetings are also attended by people other than Committee members, there can be more than 40 people present (on average there are approximately 25 people taking part in the meeting plus observers in the public gallery). Despite the number of people in the room, the Chair tries to make everybody feel as comfortable as possible (see also section 2c below). To help everyone in the room hear, the Committee members, experts and companies all have desk microphones to use in the meeting.

## 2b Attendance

Technology Appraisals Advisory Committees are open to the public as part of NICE’s commitment to openness and transparency. We anticipate that many of these places will be taken by interested members of the public and may also include members of the press and people from stakeholder organisations including drugs companies (see section 6). It will be useful for you to consider this factor in preparation for the meeting.

The meeting will be held in 2 parts – with the first part open to the public and the second part closed to everyone except the Committee members and NICE team, this allows the Committee to make their decision making in private. If you are asked about personal or sensitive matters in the meeting which you do not wish to discuss in public, you may ask the Chair for discussion to take place in private.

Non-Committee members attending the meeting might include:

* NICE staff
* Academic researchers who write a report on the evidence for the appraisal)
* Pharmaceutical companies whose product is being evaluated
* Clinical Experts and other Patient Experts
* Observers (usually members of NICE staff attending as part of a training programme, or people researching NICE or the appraisal process)
* Members of the public (observing – see section 6)

Usually, you will have the opportunity to meet with a member of the Public Involvement Programme and the other experts before the meeting. Sometimes it will also be possible to introduce you to the Committee Chair, the NICE Project Manager and Lay Members of the Committee. We hope this will help experts feel comfortable and welcome at the meeting and make participating in the meeting easier. Please feel free to ask these people any outstanding questions you may have before the meeting starts.

## 2c Meeting style

Committee meetings follow a relatively formal process, but the Committee Chair will try and make it as welcoming as possible. This is necessary because of the large number of people involved in the meeting; it also helps the process to be consistent across all appraisals. For most appraisals, the members of the Committee will usually be on first name terms and the tone of the meeting will be friendly. Committee meetings may have more than 1 technology appraisal on the agenda; therefore, Committee members may have already been involved in several hours of discussion before you are invited to join the meeting.

## 2d Introductions

All experts, including the Patient Experts, are expected to introduce themselves briefly to the Committee.

Introduce yourself as a Patient Expert, and briefly, in no more than a minute or so, outline your experience of the condition and therapies being appraised. You will **not** be asked to give a presentation on your experience as the committee has been given a copy of your personal statement. Even though an organisation has nominated you, you are at the meeting to give your personal views as an individual.

## 2e Conflict of interest

The next stage of the meeting involves all the people taking part in the discussion making a ‘declaration of interest’. This is a process where everyone is asked to say whether they have any personal or professional involvement with a company or product that might affect their objectivity (for example, if their position or department is funded by a pharmaceutical company). Sometimes, the Patient and Clinical Experts are asked to make the declarations as part of their introduction or when the Committee members are asked for theirs. Unless you have received payments from, or own shares in, the company whose products are being appraised, or a company whose products are being used as a comparison, you can simply answer ‘none’ when it is your turn to declare your interests.

## 2f The Presentation

After the introductions and ‘declarations of interests’, 2 or 3 members of the Committee (the ‘lead team’), will give a presentation in 2 parts. The first part of the presentation outlines the clinical issues relating to the condition and the technology. This part also includes patients’ issues prepared by the lead Lay Member of the Committee for this topic (see section 1a). If information provided by the Patient Expert is received early enough, it is often incorporated in the slides prepared by the ‘lay lead’ and presented to the Committee. The second part addresses issues of cost effectiveness. The presentations are essentially a summary of the evidence submitted to the Committee and aim to raise the key issues for discussion at the meeting.

While listening to the part of the presentation dealing with clinical issues, it is helpful for you to consider the following questions:

* Has the condition been defined correctly?
* Has the condition been fully represented?
* Have the ‘problems’ (if any) of the technology been fully represented?
* Have the ‘benefits’ (if any) of the technology been fully represented?
* Is the summary at the end of the presentation accurate?
* Do the key issues identified at the end of the presentation include key issues for patients?

The part of the presentation dealing with issues of cost effectiveness is more technical than the first because it deals with ‘health-economic modelling’. Although it may be difficult for you to input into this part of the presentation, it is relevant to consider the following points:

* Have the clinical trials presented in the written documentation used a ‘quality-of-life measure’?
* If so, has this measurement taken into account the quality-of-life issues that are important to patients?

The committee may well be discussing “end of life” criteria and “mortality” rates. We understand this can be quite difficult to listen to when the information affects you personally. If at any point during the meeting you wish to leave the meeting momentarily please do not hesitate to do so.

## 2g Committee discussion

At the end of the presentation, there will be a summary of the main issues for discussion. The Chair and Committee members will seek clarification of the issues from the experts (Patient and Clinical Experts). Many questions will be directed at the expert panel rather than at the Patient Experts alone, although it is likely that at least some of the questions will be put specifically to the Patient Experts. The experts are asked a number of questions but are also encouraged to raise issues themselves and to participate fully in the Committee’s discussion. You are not expected to comment in detail on the health-economic issues but are welcome to do so if you wish.

As noted earlier, the second part of the meeting will be put aside for dealing with issues of a more confidential nature without members of the public in attendance. You are entitled to request that the Chair holds a private session; however, this request must be made before the meeting (see section 1b above – ‘Preparation’).

The Committee is primarily made up of clinicians and other experts including health economists from the NHS and universities. It can sometimes be difficult for Patient Experts to answer questions that are put to the expert panel (Clinical and Patient Experts) as a whole. It is important, however, that you are proactive in answering questions and in raising issues that you think are important.The Patient Expert role is taken seriously by the Committee and the Chair will ensure that you get an opportunity to speak if you would like to make a comment. The following points may be helpful:

* *Don’t wait to be asked a question*– if you have a comment to make about the presentation or want to ask questions to the Committee or the other experts, make it clear to the Chair that you have something to say.
* *If you want to make a point* – keep your arm raised until you are sure that the Chair has seen you. The Chair will keep a list of people who have indicated that they have something to say and he or she will take each comment in turn.
* *When you are speaking –* if face to face switch your desk microphone on and talk into it as it will help everybody hear what you are saying.
* *The primary role of a Patient Expert –* is to ensure that the patient’s experience is explained so that it can be taken into account.
* *Give a balanced view*– evidence from patients is most effective if you address both positive and negative aspects on the use of a given technology.

## 2h Equalities

At NICE, we are committed to promoting equality and eliminating unlawful discrimination in our activities and guidance we produce.

The Committee has to bear in mind that a person’s treatment should not be determined by their race, sex, disability, age, religion or belief, sexual orientation, gender reassignment or the fact that they are pregnant or have recently given birth. Equality issues can extend beyond these factors to any group of people that can be identified collectively as sharing a common characteristic and could need protection from discrimination.

Please bring to the Committee’s attention if you think that this appraisal could:

* exclude any patients for which this treatment is licensed but who are protected by the equality legislation
* lead to recommendations that have a different impact on people protected by the equality legislation than on the wider population
* lead to recommendations that have any adverse impact on people with a particular disability or disabilities.

More information about equalities at NICE is available in [NICE’s equality scheme](http://www.nice.org.uk/About/Who-we-are/Policies-and-procedures/NICE-equality-scheme).

## 2i Closing Comment

When the Chair is satisfied that the experts have been asked all the relevant questions, the experts may be invited to make a closing comment. Although you are by no means obliged to make a closing comment, this is an opportunity to emphasise any important points and to add any information that you may feel has been overlooked. Even though you are about to leave the meeting, the decision on the technology has not yet been made and what you say here can still have an impact. This is the opportunity for any evidence that you think has been missed rather than a request to have the treatment recommended.

# 3 After you leave the meeting

# *3a The committee decision*

Part 2 of the meeting continues after the experts, companies and members of the public leave the meeting. The Committee must consider the impact of their decision on all patients and the NHS as a whole.

Often, a new treatment may be better but more expensive than a previous treatment. Every time NICE recommends the use of such a technology (drug or medical device) to the NHS, savings from existing budgets have to be made to pay for the new treatment. In practice, this often means that something else can no longer be paid for. The Committee need to be as certain as possible that the effectiveness and benefits of the new therapy would outweigh the potential cut of a service or treatment for patients with the same or other conditions. You may hear the Committee refer to this as ‘opportunity costs’.

The Committee discussion is based around all the evidence, which includes:

* The Assessment Report (multiple technology appraisals only)
* Consultee and commentator comments on the Assessment Report (multiple technology appraisals only)
* Pharmaceutical company(ies)’ evidence submission(s)
* External Assessment Group (EAG) *(previously Evidence Review Group (ERG)* report (single technology appraisals only)
* Patient and carer organisation’s written submissions of evidence
* Professional organisation’s written submissions of evidence
* Patient and Professional Experts’ personal statements
* Responses to the technical engagement stage (if applicable)
* The academic groups responses to the Committee’s questions External Assessment Group (EAG) for STA and Assessment Group for MTA)
* Responses given by experts to the Committee’s questions
* Responses given by the company to the Committees questions

Based on all the evidence, the Committee considers 2 main things:

1. i) *Clinical effectiveness* – how well the treatment or therapy works, compared with current treatment in the NHS?
2. ii) *Cost effectiveness* – is the new treatment or therapy good value for public money, compared with current treatment in the NHS?

To do this, NICE uses a measure known as QALYs (quality-adjusted life years). You will hear this discussed in the part of the meeting that you attend. QALYs consider quality of life, as well as length of life. They are a standard measure allowing evidence to be presented in a standard way so that the Committee can make decisions about treatments for completely different conditions in the same way.

## Example of how a QALY is calculated

Patient X has a serious, life-threatening condition.

* If he continues receiving standard treatment, he will live for 1 year, with a quality of life of 0.4 (0 or below = worst possible health, 1 = best possible health)
* If he receives the new drug, he will live for 1 year 3 months (1.25 years), with a quality of life of 0.6.

The new treatment is compared with standard care in terms of the QALYs gained:

* Standard treatment: 1 (year's extra life) × 0.4 = 0.4 QALY
* New treatment: 1.25 (1 year, 3 months extra life) × 0.6 = 0.75 QALY

The new treatment leads to 0.35 additional QALYs (that is: 0.75–0.4 QALY = 0.35 QALYs).

When we calculate how much it costs (including drug price, but also hospital costs, tests and check-ups) per QALY of benefit, the answer that we get is an ICER (Incremental Cost Effectiveness Ratio).

## Example of how an ICER is calculated

If the cost of the new drug is assumed to be £10,000 and standard treatment costs £3000, then the difference in treatment costs is £7000.

The difference in treatment costs is then divided by the difference in QALYs to calculate the cost per QALY gained.

The ICER is 7000 ÷ 0.35 = £20,000 per QALY gained.

If the ICER calculation shows the new treatment or therapy is ‘good value for money’, the treatment will normally be approved (the Committee will use the term ‘cost effective’). If the benefits of the treatment are outweighed by the costs, the ICER is likely to be high, and then the treatment is not considered to be ‘good value’ for public money (not ‘cost effective’), and will normally not be approved.

NICE currently considers treatments or therapies that have an ICER:

* under £20,000, to be cost effective
* between £20,000 and £30,000, to sometimes be cost effective depending on the strength of the evidence
* over £30,000, to be rarely cost effective unless there are very special circumstances.

For Highly Specialised Technologies (HST) the cost effectiveness thresholds are higher than illustrated above.

The data that are used in the calculations are sometimes not clear, and so the Committee would need help understanding the information. The Committee asks the experts questions in the first part of the meeting and gets the views of stakeholders from written submissions. There are other things that the Committee thinks about, not just the ICERs. These include patient preferences, reliability and clarity of the data, whether the new treatment or therapy is innovative, whether the condition is considered severe, and whether there are special ‘equalities’ issues (the need to consider the effect of the decision on protected groups, such as disabled people – see section 2h above).

## 3b After the committee decision

The Committee’s discussions will agree on the contents of the draft guidance.

One of the following 2 processes will be followed:

1. If the guidance is broadly in line with the licence for the therapy, there is no formal consultation. The Committee produce a Final Draft Guidance (FDG) *(previously Final Appraisal Document (FAD)* directly from this first meeting and it contains the final recommendations made by the Committee to NICE.
2. If the guidance is restrictive however, the Committee produces a Draft Guidance *(previously Appraisal Consultation Document (ACD) (Evaluation Consultation Document or ECD for HST).* This is draft NICE guidance and is completed 3 weeks (15 working days) after the Committee meeting. It is sent out to all consultees, commentators and experts for comments, and is posted on the NICE website for open public consultation 1 week later (5 working days).

Consultees, commentators and experts have 4 weeks (20 working days) to comment on the Draft Guidance*.* As comments can result in changes to the document, it is also a good idea for Patient Experts to submit their own formal written comments, individually or jointly with the nominating organisation. Please do not use the website to send your comments, as this is only for the general public.

After comments on the Draft Guidance have been collated, Committee members reconvene at a second meeting to review their recommendations in light of the comments received. In this meeting, the Chair summarises the first meeting and takes the Committee through the comments that have been received. Following the meeting the Committees final decision then forms the contents of a Final Draft Guidance (FDG)

Experts are only occasionally invited back to the second Committee meeting if the Chair feels that more clarification is needed. (If you wish to observe the second meeting, please see section 6.).

In both processes, if the patient organisations that have been involved in the appraisal are not happy with the proposed guidance, they have the option of appealing through the formal appeals process. Appeals against a Final Draft Guidance (FDG) can be lodged if:

The grounds of appeal are:

Ground 1: In making the assessment that preceded the recommendation, NICE has:

1. failed to act fairly  
   or
2. exceeded its powers

Ground 2: The recommendation is unreasonable in the light of the evidence submitted to NICE.

The Public Involvement Programme staff at NICE are available to answer queries, but cannot assist organisations who are appealing against an appraisal decision with their appeal. There is a “[Guide to the technology appraisal and highly specialised technologies appeal process](http://www.nice.org.uk/article/pmg18/chapter/Foreword)” for more help on appealing.

# 4 Expenses and honorarium

Patient Experts can claim a £75 fee (or honorarium) as well as travel and subsistence costs for attending a NICE Technology Appraisal Committee meeting. Please see our [policy](https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/non-staff-reimbursement-policy.pdf) explaining your entitlement. If you cannot access the link to our policy above please contact [PIPlayexpenses@nice.org.uk](mailto:PIPlayexpenses@nice.org.uk)

Key areas and reminders are highlighted below:

## 4a £75 fee (or honorarium)

You can claim £75 for attending the committee meeting. When you use the online expenses system (see 4e below) you choose the option on the left hand side called ‘Honorarium-Lay member’ to claim.

## 4b Travel

NICE has a central booking facility for train, air travel and accommodation. We aim to reduce the burden of costs for individuals and aim to book (and pay for) all train, air travel and accommodation where applicable in advance. The committee operations team will contact you to make the necessary arrangements and will make your booking for you. However, if you arrange your own travel by public transport or taxi, it is important to keep any tickets or receipts relating to the journey, so that you can submit them with your claim. If you plan to travel by car, please note that there is standard allowance per mile set out in our policy – see the link above.

## 4c Subsistence

If you attend the meeting for 5 hours or more including travel time from your home or office, then you are entitled to claim subsistence for food and drink. Rather than claiming back what you actually eat, we have set rates depending on how long you are away (from home or office). This means that you do not need to provide us with receipts for food and drink. The full information is set out in Appendix 1 of the [policy.](https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/Non-Staff-Travel-Subsistence-and-General-Expenses-Policy-and-Procedures.pdf) Here is a quick summary:

|  |  |
| --- | --- |
| **Time away from home or office including travel time** | **Allowance** |
| 5 hours | £5 |
| 10 hours | £10 |
| 24 hours (breakfast provided) | £20 |
| 24 hours (breakfast not provided) | £25 |

Occasionally, depending on the timing and length of a Committee meeting, Patient Experts are invited to join the Committee for lunch. In this case, you do not need to claim subsistence to cover lunch. Also, if NICE has booked an overnight stay in the hotel for you and breakfast is included, then you cannot claim subsistence for breakfast. Please note that if you book your own hotel NICE has a cap on the amount that we can reimburse you. Please refer to the policy for full details of the hotel cap and example scenarios for the subsistence allowance.

## 4d Carer expenses

To help Patient Experts attend our Committee meetings, we provide expenses to pay for carers if you need them. This includes childcare and caring for an ill or disabled person.

Additionally, if you need a carer or personal assistant specifically to enable you to attend a meeting when you would otherwise be unable to do so, we will pay for their travel and subsistence expenses in line with the Patient Experts’. We will also reimburse the cost of hiring a carer (up to a maximum of £10 per hour or £60 per day). If you would like more information, please see the [policy](https://www.nice.org.uk/Media/Default/About/Who-we-are/Policies-and-procedures/Non-Staff-Travel-Subsistence-and-General-Expenses-Policy-and-Procedures.pdf) or let us know.

## 4e How to make your claim

You need to make your expenses claim within **3 months of the date** of the meeting. Please use the [online expenses system](https://nice1.sel-expenses.com/shared/logon.aspx?ReturnUrl=%2f.) with scanned copies of all required receipts attached.

If you do not have access to the online system or have difficulties when using it, please let us know so that you can use the paper system which will take a little longer. You will still need to give us your receipts.

**Please note** that your expenses will be paid into your bank account as we can no longer issue cheques.

Please also note that following the meeting a member of the PIP team will email you with more detailed information on how to make your expenses claim.

# 5 What to do if you are contacted by the press

In the development of most NICE technology appraisals, press releases are often produced. These coincide with the publication of the Draft Guidance and Final Draft Guidance (FDG). They may be produced by NICE, the company and sometimes registered patient and carer organisations. A press release may be issued under embargo the day before publication. It is possible you may be contacted by the media then or on the publication day itself.

As with all things related to the media, the interest in any particular appraisal will be dependent on what else is in the news on the day. If you are approached and are willing to take part in interviews you may do so, but please be mindful that the Draft Guidance and Final Draft Guidance (FDG) do not constitute final guidance to the NHS. If asked about your attendance at the Committee meeting, please do not quote any of the Committee members directly.If a journalist asks about future dates or timescales or anything you are unsure of, please refer them to the press office at NICE (0845 003 7782) who can help them.

# 6 Observing committee meetings from the public gallery

Our Committee meetings are open to the public, including the general public, members of patient and carer organisations, the press and companies (often drugs companies). We welcome observers from your nominating organisation, or if you have friends or family who would like to observe, then they are also welcome.

There is often a second Committee meeting 2 months after the meeting you attend. Patient and Clinical Experts are not often invited back to participate in the second meeting. This is because the evidence gathering and clarification stage finishes in the first meeting. In the second meeting, the Committee considers the comments received about the Draft Guidance. However, you, and members of your nominating organisation, are welcome to observe from the public gallery.

People in the public gallery can stay for the first part of the meeting – the part attended by the Patient and Clinical Experts and the companies. Unlike Patient Experts, members of the public gallery are there to observe only and not take part. Members of the public are not allowed to record (either audio or video), take photographs or use laptops, but they can take handwritten notes. They cannot quote you or any of the Committee members directly.

To attend the public gallery, you need to register via our [website](http://www.nice.org.uk/Get-Involved/Meetings-in-Public), 20 working days before the meeting. You will receive an email from the Committee team letting you know when registration is open, along with the registration link.

Please note that people in the public gallery are observers only and not participants, so we cannot provide expenses.

If you would like any more information about observing meetings from the public gallery, please contact [pip@nice.org.uk](mailto:pip@nice.org.uk) or call 0161 870 3020.

## Checklist

## Before the meeting

* Have you sent in your short personal statement to NICE, or indicated you agree with your nominating organisation’s submission?
* Have you returned your confidentiality agreement to NICE?
* Have you thought about any sensitive information that you would like the Committee to consider in a closed session, and contacted the Chair if appropriate?
* Have you read through the NICE and Public Involvement Programme documents explaining the appraisals process?
* Do you feel that you have a basic understanding of the appraisals process?
* Do you understand your role in the appraisals process?
* Are you familiar with the submission of evidence from your organisation?
* Have you attended the patient expert briefing meeting offered by the public involvement team.
* Have you spoken to your named public involvement adviser to ask any last-minute questions?

If you answered ‘no’ to any of these questions, please contact the Public Involvement Programme as soon as possible.

## At the meeting

* Do you have a pen and paper as it will be helpful to make notes in the meeting?
* Are you familiar with the questions you need to think about when listening to the presentations?
* Are you aware that you can request, of the Chair, that any personal or sensitive information you would like to raise can be considered in private?
* Do you know how best to get yourself heard at the meeting?
* Remember to keep in mind the limitations of the NICE remit.

## After the meeting

* If you want to, jot down a few notes to describe your experience as a Patient Expert.
* Remember to comment on the Draft Guidance when it is distributed – this will usually be 3 weeks after the meeting. All consultees have 4 weeks to submit comments.

## Contact details for the Public Involvement Programme

[pip@nice.org.uk](mailto:pip@nice.org.uk) 0161 870 3020